Skip to main
QNCX

QNCX Stock Forecast & Price Target

QNCX Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 80%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Quince Therapeutics is well-positioned for success with its innovative AIDE technology and promising Phase 3 asset eDSP, which leverages the AIDE technology to encapsulate the drug DSP into a patient's own red blood cells. The company's focus on rare diseases and its differentiated approach to targeting vascular remodeling in pulmonary hypertension set it apart from other companies in the biotechnology space. Additionally, the upcoming data readouts for its Phase 2 BOS and PH-ILD trials provide potential catalysts for the stock. With its strong pipeline and potential for multiple blockbuster commercial opportunities, Quince Therapeutics is a stock to watch.

Bears say

Quince Therapeutics is up 85% in the last few weeks, making its undervaluation even more apparent. Despite the promising potential of LAM-001 and PH-ILD as the primary driver of the story, there may be challenges in replicating the initial human PH data and the lack of upcoming catalysts for ~1 year, creating a potential catalyst vacuum for the company.

QNCX has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 80% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Quince Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Quince Therapeutics Inc (QNCX) Forecast

Analysts have given QNCX a Buy based on their latest research and market trends.

According to 5 analysts, QNCX has a Buy consensus rating as of Sep 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Quince Therapeutics Inc (QNCX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.